WO2006055704A3 - Anticorps diriges contre des proteines ten-m et utilisations associees - Google Patents

Anticorps diriges contre des proteines ten-m et utilisations associees Download PDF

Info

Publication number
WO2006055704A3
WO2006055704A3 PCT/US2005/041673 US2005041673W WO2006055704A3 WO 2006055704 A3 WO2006055704 A3 WO 2006055704A3 US 2005041673 W US2005041673 W US 2005041673W WO 2006055704 A3 WO2006055704 A3 WO 2006055704A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antibodies directed
light chain
immunoglobulin molecules
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/041673
Other languages
English (en)
Other versions
WO2006055704A2 (fr
Inventor
Jaspal Kang
Seth Ettenberg
John Herrmann
Luca Rastelli
Michael E Jeffers
William Larochelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Amgen Fremont Inc
Original Assignee
CuraGen Corp
Abgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CuraGen Corp, Abgenix Inc filed Critical CuraGen Corp
Publication of WO2006055704A2 publication Critical patent/WO2006055704A2/fr
Publication of WO2006055704A3 publication Critical patent/WO2006055704A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps entièrement humains dirigés contre Ten-M4 et des utilisations de ces anticorps. La présente invention porte également sur des anticorps monoclonaux humains dirigés contre Ten-M4, sur des séquences polynucléotidiques isolées codant pour des molécules d'immunoglobuline à chaînes légères et lourdes, sur des séquences d'acide aminé comprenant des molécules d'immunoglobuline à chaînes légères et lourdes, en particulier sur des séquences correspondant à des séquences contiguës à chaînes légères et lourdes couvrant les régions structurales (FR) et/ou les régions déterminant la complémentarité (CDR). L'invention concerne aussi des hybridomes et d'autres lignées cellulaires exprimant ces molécules d'immunoglobuline et ces anticorps monoclonaux. Certains anticorps peuvent inhiber les métastases de tumeurs, et certains peuvent servir à libérer un agent, tel qu'une toxine, dirigé vers une cible particulière.
PCT/US2005/041673 2004-11-17 2005-11-17 Anticorps diriges contre des proteines ten-m et utilisations associees Ceased WO2006055704A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62913204P 2004-11-17 2004-11-17
US60/629,132 2004-11-17

Publications (2)

Publication Number Publication Date
WO2006055704A2 WO2006055704A2 (fr) 2006-05-26
WO2006055704A3 true WO2006055704A3 (fr) 2006-10-12

Family

ID=36407748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041673 Ceased WO2006055704A2 (fr) 2004-11-17 2005-11-17 Anticorps diriges contre des proteines ten-m et utilisations associees

Country Status (1)

Country Link
WO (1) WO2006055704A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682093A1 (fr) * 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Anticorps, procedes et kits de diagnostic et de traitement de melanomes
WO2008120203A2 (fr) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Procédés de diagnostic et de traitement de maladies provoquées par le cytomégalovirus
EP2356251A1 (fr) 2008-11-07 2011-08-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurine et cancer
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (fr) 2011-09-26 2013-04-04 Kymab Limited Chaînes légères substituts (cls) chimères comprenant vpreb humain
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057453A2 (fr) * 2000-12-19 2002-07-25 Curagen Corporation Polypeptides et acides nucleiques codant ces derniers
WO2003076578A2 (fr) * 2002-03-06 2003-09-18 Curagen Corporation Polypeptides therapeutiques, acides nucleiques codant pour eux et leur procede d'utilisation
WO2004070011A2 (fr) * 2003-02-01 2004-08-19 Tanox, Inc. Anticorps ige anti-humains a affinite elevee

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057453A2 (fr) * 2000-12-19 2002-07-25 Curagen Corporation Polypeptides et acides nucleiques codant ces derniers
WO2003076578A2 (fr) * 2002-03-06 2003-09-18 Curagen Corporation Polypeptides therapeutiques, acides nucleiques codant pour eux et leur procede d'utilisation
WO2004070011A2 (fr) * 2003-02-01 2004-08-19 Tanox, Inc. Anticorps ige anti-humains a affinite elevee

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEN-ZUR T ET AL: "The mammalian Odz gene family: Homologs of a drosophila pair rule gene with expression implying distinct yet overlapping developmental roles", DEVELOPMENTAL BIOLOGY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 217, January 2000 (2000-01-01), pages 107 - 120, XP002190347, ISSN: 0012-1606 *
FENG KANG ET AL: "All four members of the Ten-m/Odz family of transmembrane proteins form dimers", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 29, 19 July 2002 (2002-07-19), pages 26128 - 26135, XP002391097, ISSN: 0021-9258 *
OOHASHI T ET AL: "Mouse ten-m/Odz is a new family of dimeric type II transmembrane proteins expressed in many tissues", THE JOURNAL OF CELL BIOLOGY, ROCKEFELLER UNIVERSITY PRESS, US, vol. 145, no. 3, 3 May 1999 (1999-05-03), pages 563 - 577, XP002237529, ISSN: 0021-9525 *
ZHOU XIAO-HONG ET AL: "The murine Ten-m/Odz genes show distinct but overlapping expression patterns during development and in adult brain.", GENE EXPRESSION PATTERNS, vol. 3, no. 4, August 2003 (2003-08-01), pages 397 - 405, XP002391096, ISSN: 1567-133X *

Also Published As

Publication number Publication date
WO2006055704A2 (fr) 2006-05-26

Similar Documents

Publication Publication Date Title
WO2006055638A3 (fr) Anticorps monoclonaux entierement humains diriges contre l'il-13
WO2008112004A3 (fr) ANTICORPS DIRIGÉS CONTRE αVβ6 ET LEURS UTILISATIONS
WO2007120693A3 (fr) AGENTS DE LIAISON CIBLÉS, DIRIGÉS CONTRE L'uPAR, ET UTILISATIONS
WO2004084823A3 (fr) Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
WO2006130458A3 (fr) Anticorps diriges contre cd20 et leurs utilisations
WO2003057857A3 (fr) Anticorps diriges contre les pdgfd et utilisations
WO2004050683A3 (fr) Anticorps agissant sur le facteur de necrose des tumeurs (tnf) et leurs utilisation
WO2007070432A3 (fr) Proteines de liaison specifiques des facteurs de croissance analogues a l'insuline et utilisations de celles-ci
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
WO2006124269A3 (fr) Anticorps monoclonaux humains se fixant a l'antigene-1 tres tardif pour le traitement de l'inflammation ainsi que d'autres troubles
WO2006081139A3 (fr) Anticorps diriges contre interleukine-1 beta
WO2006104978A3 (fr) Anticorps dirigés contre les antigènes majeurs de la ténascine
WO2006113643A3 (fr) Anticorps monoclonaux entierement humains a affinite elevee d'interleukine-8 et epitopes destines a ces anticorps
WO2004050850A3 (fr) Anticorps diriges contre la phospholipase a2 et utilisations
WO2006055704A3 (fr) Anticorps diriges contre des proteines ten-m et utilisations associees
WO2007109307A3 (fr) Anticorps dirigés contre la protéine 4 du type angiopoïétine et utilisations de ceux-ci
WO1998050433A3 (fr) Anticorps monoclonaux humains contre le recepteur du facteur de croissance epidermique
WO2004016769A3 (fr) Anticorps diriges contre la proteine chimioattractive monocytaire 1 (mcp-1) et leurs utilisations
WO2005016111A3 (fr) Anticorps diriges vers l'hormone parathyroide et leurs utilisations
WO2008133641A3 (fr) Anticorps dirigés contre la gpnmb et leurs utilisations
WO2005047328A3 (fr) Anticorps diriges contre l'inhibiteur de la protease des leucocytes secreteurs
EP2548583A3 (fr) Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
WO2006068975A3 (fr) Proteines de liaison specifiques de la matriptase humaine
WO2007065037A3 (fr) Anticorps dirigés contre mmp-13 (collagénase-3) et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05848194

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05848194

Country of ref document: EP

Kind code of ref document: A2